Naltrexone's suppressant effects on drinking are limited to the first 3 months of treatment

Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
Psychopharmacology (Impact Factor: 3.88). 10/2007; 194(1):1-10. DOI: 10.1007/s00213-007-0807-y
Source: PubMed


Twelve weeks of naltrexone significantly improves drinking outcomes in alcoholics; however, the clinical benefits of naltrexone decline shortly after treatment is discontinued.
The present study investigated whether extended treatment with naltrexone significantly improved drinking outcomes.
One hundred forty-six alcohol-dependent patients received broad spectrum treatment or motivational enhancement therapy and either 12 or 24 weeks of naltrexone. The primary dependent variables were percent days abstinent and percent heavy drinking days.
Using an intention-to-treat analysis, there were no significant differences in percent days abstinence or percent heavy drinking days at the end of phase 2 between patients who received 24 weeks of treatment with naltrexone (chi = 63.23) or patients who received 12 weeks of treatment with naltrexone followed by 12 weeks of treatment with placebo (chi = 65.82). Similarly, the average percent heavy drinking days was not significantly different at the end of phase 2 between the group that received 24 weeks of naltrexone (chi = 21.9) and the group that received 12 weeks of naltrexone followed by 12 weeks of placebo (chi = 22.14). Medication compliance was low in the second phase of the study. Drinking outcomes declined with declining compliance whether patients were taking naltrexone or placebo.
The results of this study suggest that administering naltrexone beyond an initial 12 weeks of treatment may not be beneficial to all patients and should be administered along with close medical monitoring to insure compliance.

5 Reads
  • M Soyka ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Pharmacologically supported relapse prevention of alcohol dependence with so-called anticraving substances is still a relatively new clinical field. Apart from disulfiram, which when alcohol is consumed results in massive intolerance reactions, for many years there have been no promising pharmacological approaches to improving prognosis in alcohol dependence. By now there has been a clearcut improvement in knowledge of the neurobiological basis of alcohol dependence and basic addiction mechanisms, such as, for example, craving. A solidly evidence-based finding by now is that acamprosat reduces the risk of relapse in alcohol dependence by acting via glutamatergic neurons with largely good tolerance. The effectiveness of the opioid antagonist naltrexon in the treatment of alcohol dependence is also solidly evidence-based. Naltrexon's main action is to lower the positive-reinforcing effect of alcohol vectored by opiate receptors. New clinically relevant developments may be another opioid antagonist, nalmefen, and the use of depot-naltrexon, which could markedly improve the compliance problem. A number of investigations of the two substances have been published or are under evaluation. Other substances for which at least first research results are available are GABA-B receptor agonist baclofen, the antiepileptics topiramat and gabapentin, daidzen, the drug derived from Chinese medicine which is probably an alcohol dehydrogenase inhibitor, and the atypical neuroleptic quetiapin. Substances resulting in modulation of the stress system may also be of clinical interest. To date, biologically-oriented addiction research has failed to produce a "magic bullet" to improve the prognosis or reduce the risk of relapse in alcohol dependence, but the first evidence-based therapeutic approaches exist.
    MMW Fortschritte der Medizin 06/2008; 150 Suppl 2(7):22-4.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper is the thirtieth consecutive installment of the annual review of research concerning the endogenous opioid system. It summarizes papers published during 2007 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides, opioid receptors, opioid agonists and opioid antagonists. The particular topics that continue to be covered include the molecular–biochemical effects and neurochemical localization studies of endogenous opioids and their receptors related to behavior, and the roles of these opioid peptides and receptors in pain and analgesia; stress and social status; tolerance and dependence; learning and memory; eating and drinking; alcohol and drugs of abuse; sexual activity and hormones, pregnancy, development and endocrinology; mental illness and mood; seizures and neurologic disorders; electrical-related activity and neurophysiology; general activity and locomotion; gastrointestinal, renal and hepatic functions; cardiovascular responses; respiration and thermoregulation; and immunological responses.
    Peptides 12/2008; 29(12-29):2292-2375. DOI:10.1016/j.peptides.2008.09.007 · 2.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Randomized clinical trials on the effectiveness of naltrexone (NTX) in the treatment of alcohol dependence have produced conflicting results. One possible explanation for these discrepancies may lie in the various psychosocial treatments for which NTX is an adjunct. The goal of this study was to examine the interplay between psychosocial treatment and duration of NTX. One hundred and seventy-four alcohol-dependent outpatients participated in a double-blind trial where they were randomly assigned to 12 vs. 24 weeks NTX duration and to one of two psychosocial treatments: motivational enhancement therapy (MET) and broad spectrum treatment (BST), a cognitive behavioral therapy tailored to the patient's specific needs. After an initial 12-week period of NTX and psychosocial treatment, half of each psychotherapy condition was assigned to continue NTX for an additional 12 weeks while the other half was assigned to placebo. Patient drinking outcomes were measured for the year following treatment completion. It was hypothesized that the combination of extended duration of NTX and the moderate intensity of BST would be predictive of longer time to a first heavy drinking day than any of the three alternative combinations: MET with short or extended NTX administration or BST with short NTX administration. The median time to first drink and time to first heavy drinking day were found to be significantly longer for patients who received BST and extended NTX than for patients in the other three groups. These results may suggest that the kind of psychosocial treatment delivered in combination with duration of NTX administration may partially explain the inconsistent findings regarding the efficacy of NTX in the treatment of alcohol dependence.
    Psychopharmacology 08/2009; 206(3):367-76. DOI:10.1007/s00213-009-1615-3 · 3.88 Impact Factor
Show more